Epitopes involved in antibody-mediated protection from Ebola virus
- PMID: 10698744
- DOI: 10.1126/science.287.5458.1664
Epitopes involved in antibody-mediated protection from Ebola virus
Abstract
To determine the ability of antibodies to provide protection from Ebola viruses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated and evaluated for efficacy. We identified several protective mAbs directed toward five unique epitopes on Ebola glycoprotein. One of the epitopes is conserved among all Ebola viruses that are known to be pathogenic for humans. Some protective mAbs were also effective therapeutically when administered to mice 2 days after exposure to lethal Ebola virus. The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus.
Similar articles
-
Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.Clin Immunol. 2011 Nov;141(2):218-27. doi: 10.1016/j.clim.2011.08.008. Epub 2011 Aug 31. Clin Immunol. 2011. PMID: 21925951
-
Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1. J Virol. 2015. PMID: 26468533 Free PMC article.
-
Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1. J Virol. 2015. PMID: 26468532 Free PMC article.
-
Achieving cross-reactivity with pan-ebolavirus antibodies.Curr Opin Virol. 2019 Feb;34:140-148. doi: 10.1016/j.coviro.2019.01.003. Epub 2019 Mar 15. Curr Opin Virol. 2019. PMID: 30884329 Free PMC article. Review.
-
[The use of monoclonal antibodies for the treatment of Ebola virus disease.].Vopr Virusol. 2018;63(6):245-249. doi: 10.18821/0507-4088-2018-63-6-245-249. Vopr Virusol. 2018. PMID: 30641019 Review. Russian.
Cited by
-
An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.J Virol. 2016 Sep 12;90(19):8720-8. doi: 10.1128/JVI.01239-16. Print 2016 Oct 1. J Virol. 2016. PMID: 27440895 Free PMC article.
-
Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.J Virol. 2012 Dec;86(24):13467-74. doi: 10.1128/JVI.01896-12. Epub 2012 Oct 3. J Virol. 2012. PMID: 23035224 Free PMC article.
-
A thermostable, chromatographically purified Ebola nano-VLP vaccine.J Transl Med. 2015 Jul 15;13:228. doi: 10.1186/s12967-015-0593-y. J Transl Med. 2015. PMID: 26174690 Free PMC article.
-
Therapeutic applications of monoclonal antibodies.Am J Med Sci. 2002 Jul;324(1):14-30. doi: 10.1097/00000441-200207000-00004. Am J Med Sci. 2002. PMID: 12120821 Free PMC article. Review.
-
Role of natural killer cells in innate protection against lethal ebola virus infection.J Exp Med. 2004 Jul 19;200(2):169-79. doi: 10.1084/jem.20032141. Epub 2004 Jul 12. J Exp Med. 2004. PMID: 15249592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical